{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:05:27Z","timestamp":1792209927466,"version":"4.4.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is commonly diagnosed in older adults, in particular the wild-type (ATTRwt), which is regarded as an age-related disease. With an aging population and improved diagnostic techniques, the prevalence and incidence of ATTR-CM will continue to increase. With increased availability of mortality reducing ATTR-CM therapies, patients are living longer. The predominant clinical manifestation of ATTR-CM is heart failure, while other cardiovascular manifestations include arrhythmia and aortic stenosis. Given their older age at diagnosis, patients often present with multiple age-related comorbidities, some of which can be exacerbated by ATTR, including neurologic, musculoskeletal, and gastrointestinal problems. Considerations related to older patient care, such as frailty, cognitive decline, polypharmacy, falls\/mobility, functional capacity, caregiver support, living environment, quality of life and establishing goals of care are particularly important for many patients with ATTR-CM. Furthermore, the high cost ATTR treatments has increased interest in establishing improved predictors of response to therapy, with assessment of frailty emerging as a potentially important determinant. Multidisciplinary care inclusive of collaboration with geriatric and elder care medicine specialists, and others such as neurology, orthopedic surgery, electrophysiology and transcatheter aortic valve replacement clinics, is now an important component of ATTR-CM management. This review will examine current aspects of the management of older ATTR-CM patients, including shared care with multiple medical specialists, the emerging importance of frailty assessment and other considerations for using ATTR therapies.<\/jats:p>","DOI":"10.3389\/fcvm.2022.863179","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T04:59:28Z","timestamp":1652763568000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Assessment and Management of Older Patients With Transthyretin Amyloidosis Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond"],"prefix":"10.3389","volume":"9","author":[{"given":"Biobelemoye","family":"Irabor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowell M.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/ehf2.13443","article-title":"Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature","volume":"8","author":"Adam","year":"2021","journal-title":"ESC Heart Failure"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am College Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"American heart association heart failure and transplantation committee of the council on clinical cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American heart association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.cjca.2019.12.034","article-title":"Canadian cardiovascular society\/Canadian heart failure society joint position statement on the evaluation and management of patients with cardiac amyloidosis","volume":"36","author":"Fine","year":"2020","journal-title":"Canadian J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cardfail.2016.10.008","article-title":"Transthyretin cardiac amyloidosis in older","volume":"22","author":"Brunjes","year":"2016","journal-title":"Am J Cardiac Failure"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Non-biopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s12350-020-02455-z","article-title":"Addendum to ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2\u2014evidence base and standardized methods of imaging","volume":"28","author":"Dorbala","year":"2021","journal-title":"J Nuc Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"European Heart J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Castano","year":"2016","journal-title":"J Am College Cardiol"},{"key":"B12","first-page":"391","article-title":"Senile systemic amyloidosis","volume":"117","author":"Pitk\u00e4nen","year":"1984","journal-title":"Am J Pathol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/HCO.0000000000000547","article-title":"Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types","volume":"33","author":"Nativi-Nicolau","year":"2018","journal-title":"Curr Opinion Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"B15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC: Heart Failure"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1056\/NEJMcp1511175","article-title":"Heart failure with preserved ejection fraction","volume":"375","author":"Redfield","year":"2016","journal-title":"N Eng J Medicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"New Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","article-title":"Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis","volume":"3","author":"Syed","year":"2010","journal-title":"JACC: Cardiovas Imag"},{"key":"B19","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC: Cardiovas Imag"},{"key":"B20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am College Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"B22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcmg.2015.05.014","article-title":"Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis","volume":"9","author":"Ternacle","year":"2016","journal-title":"JACC: Cardiovasc Imag"},{"key":"B23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.cjca.2019.11.039","article-title":"Arrhythmias in cardiac amyloidosis: challenges in risk stratification and treatment","volume":"36","author":"Cheung","year":"2020","journal-title":"Canadian J Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Amyloidosis Research network collaborators. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"B25","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Failure"},{"key":"B26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0025-6196(12)61493-1","article-title":"Clinical significance of histopathologic patterns of cardiac amyloidosis","volume":"59","author":"Smith","year":"1984","journal-title":"Mayo Clin Proc Aug."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"B28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am College Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","article-title":"Aortic stenosis and cardiac amyloidosis: JACC review topic of the week","volume":"74","author":"Ternacle","year":"2019","journal-title":"J Am College Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s13023-021-01960-9","article-title":"Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression","volume":"16","author":"Adams","year":"2021","journal-title":"Orphanet J Rare Dis 10 03."},{"key":"B31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1017\/cjn.2020.271","article-title":"Utility of Neuropathy Screening for Wild-Type Transthyretin Amyloidosis Patients","volume":"48","author":"Russell","year":"2021","journal-title":"Can J Neurol Sci 09."},{"key":"B32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/cjn.2021.34","article-title":"Canadian guidelines for hereditary transthyretin amyloidosis polyneuropathy management","volume":"49","author":"Alcantara","year":"2022","journal-title":"Canadian J Neurol Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide\u2013guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"318","author":"Felker","year":"2017","journal-title":"Jama"},{"key":"B34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"key":"B35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Upsala J Med Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/ehf2.13131","article-title":"Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan\u00ae in transthyretin wild-type cardiac amyloidosis","volume":"8","author":"Kharoubi","year":"2021","journal-title":"ESC Heart Failure"},{"key":"B37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/13506129.2017.1330744","article-title":"How your ears can tell what is hidden in your heart: wild-type transthyretin amyloidosis as potential cause of sensorineural hearing loss inelderly-AmyloDEAFNESS pilot study","volume":"24","author":"B\u00e9quignon","year":"2017","journal-title":"Amyloid"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.3390\/jcm10153415","article-title":"Frailty in wild-type transthyretin cardiac amyloidosis: the tip of the iceberg","volume":"10","author":"Broussier","year":"2021","journal-title":"J Clin Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.arr.2017.03.005","article-title":"Relationship between depression and frailty in older adults: a systematic review and meta-analysis","volume":"36","author":"Soysal","year":"2017","journal-title":"Ageing Res Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/eurjpc\/zwaa167","article-title":"Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the council for cardiology practice (CCP), Association for acute cardio vascular care (ACVC), association of cardiovascular nursing and allied professions (ACNAP), European association of preventive cardiology (EAPC), European heart rhythm association (EHRA), council on valvular heart diseases (VHD), council on hypertension (CHT), council of cardio-oncology (CCO), working group (WG)","volume":"29","author":"Richter","year":"2022","journal-title":"Europ J Preventive Cardiol"},{"key":"B41","first-page":"39","article-title":"Optimizing geriatric care with the GERIATRIC 5","volume":"65","author":"Molnar","year":"2019","journal-title":"Can Fam Physician 01."},{"key":"B42","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1517\/14740338.2013.827660","article-title":"Clinical consequences of polypharmacy in elderly","volume":"13","author":"Maher","year":"2014","journal-title":"Expert Opin Drug Saf Jan."},{"key":"B44","first-page":"i","article-title":"Polypharmacy: a global risk factor for elderly people","volume":"6","author":"Dagli","year":"2014","journal-title":"J Int Oral Health"},{"key":"B45","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10741-021-10135-4","article-title":"Polypharmacy definition and prevalence in heart failure: a systematic review","volume":"27","author":"Beezer","year":"2021","journal-title":"Heart Fail Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000115340","article-title":"Aging, disability and frailty","volume":"52","author":"Topinkov\u00e1","year":"2008","journal-title":"Ann Nutr Metab."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e006977","DOI":"10.1161\/CIRCHEARTFAILURE.120.006977","article-title":"Polypharmacy in older adults hospitalized for heart failure","volume":"13","author":"Unlu","year":"2020","journal-title":"Circ: Heart Failure"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.amjmed.2021.03.038","article-title":"Polypharmacy in heart failure with reduced ejection fraction: progress, not problem","volume":"134","author":"Rao","year":"2021","journal-title":"Am J Med 09."},{"key":"B49","doi-asserted-by":"publisher","first-page":"7416","DOI":"10.21037\/apm-21-709","article-title":"Heart failure-the experience of living with end-stage heart failure and accessing care across settings","volume":"10","author":"Chester","year":"2021","journal-title":"Ann Palliat Med Jul."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e006502","DOI":"10.1161\/CIRCHEARTFAILURE.119.006502","article-title":"Prognostic awareness and goals of care discussions among patients with advanced heart failure","volume":"13","author":"Gelfman","year":"2020","journal-title":"Circulation: Heart Failure"},{"key":"B51","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.cjca.2021.01.015","article-title":"Establishing a cardiac amyloidosis clinic: a practical primer for cardiologists","volume":"37","author":"Davis","year":"2021","journal-title":"Canadian J Cardiol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jacc.2017.06.024","article-title":"Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study","volume":"70","author":"Afilalo","year":"2017","journal-title":"J Am College Cardiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jacc.2013.09.070","article-title":"Frailty assessment in the cardiovascular care of older adults","volume":"63","author":"Afilalo","year":"2014","journal-title":"J Am College Cardioly"},{"key":"B54","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet Mar 02."},{"key":"B55","doi-asserted-by":"publisher","first-page":"100960","DOI":"10.1016\/j.arr.2019.100960","article-title":"Frailty as a predictor of adverse outcomes in hospitalized older adults: a systematic review and meta-analysis","volume":"56","author":"Cunha","year":"2019","journal-title":"Ageing Res Rev 12."},{"key":"B56","doi-asserted-by":"publisher","first-page":"b4460","DOI":"10.1136\/bmj.b4460","article-title":"Slow walking speed and cardiovascular death in -unctioning older adults: prospective cohort study","volume":"339","author":"Dumurgier","year":"2009","journal-title":"BMJ Nov 10."},{"key":"B57","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.jacc.2007.05.030","article-title":"Baseline functional performance predicts the rate of mobility loss in persons with peripheral arterial disease","volume":"50","author":"McDermott","year":"2007","journal-title":"J Am College Cardiology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.ahj.2013.07.032","article-title":"Frailty and risk for heart failure in older adults: the health, aging, and body composition study","volume":"166","author":"Khan","year":"2013","journal-title":"Am Heart J"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.jacc.2010.06.039","article-title":"Gait speed as an incremental predictor of mortality and major morbidity in elderly patients undergoing cardiac surgery","volume":"56","author":"Afilalo","year":"2010","journal-title":"J Am College Cardiol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/jgs.14776","article-title":"Transcatheter aortic valve replacement in the care of older persons with aortic stenosis","volume":"65","author":"Talbot-Hamon","year":"2017","journal-title":"J Am Geriatr Soc 04."},{"key":"B61","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1161\/CIRCOUTCOMES.111.961375","article-title":"Influence of frailty and health status on outcomes in patients with coronary disease undergoing percutaneous revascularization","volume":"4","author":"Singh","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes Sep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e008105","DOI":"10.1161\/CIRCHEARTFAILURE.120.008105","article-title":"Prevalence and prognostic significance of frailty among patients with transthyretin amyloidosis cardiomyopathy","volume":"14","author":"Fine","year":"2021","journal-title":"Circ Heart Fail 06."},{"key":"B63","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Afilalo","year":"2021","journal-title":"Europ J Heart Failure"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1161\/CIRCULATIONAHA.120.045966","article-title":"Willingness to pay for high-cost medications","volume":"141","author":"Hlatky","year":"2020","journal-title":"Circulation Apr."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.3346\/jkms.2020.35.e16","article-title":"Frailty and comprehensive geriatric assessment","volume":"35","author":"Lee","year":"2020","journal-title":"J Korean Med Sci Jan 20."},{"key":"B67","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"Jf Gerontol Series A: Biolo Sci Med Sci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/annonc\/mds619","article-title":"Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study","volume":"24","author":"Kenis","year":"2013","journal-title":"Annals Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Casta\u00f1o","year":"2015","journal-title":"Heart Fail Rev Mar."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/0002-9149(85)90995-6","article-title":"Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents","volume":"55","author":"Gertz","year":"1985","journal-title":"Am J Cardiol Jun 01."},{"key":"B71","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest Aug."},{"key":"B72","doi-asserted-by":"publisher","first-page":"989","DOI":"10.7326\/0003-4819-55-6-989","article-title":"Cardiac amyloidosis. Two cases with digitalis sensitivity","volume":"55","author":"CASSIDY","year":"1961","journal-title":"Ann Intern Med Dec."},{"key":"B73","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J Cardiovasc Electrophysiol Jul."},{"key":"B74","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart rhythm"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/j.jaccas.2020.10.004","article-title":"Disease-modifying therapy for transthyretin amyloidosis: where to start? Where to stop?","volume":"2","author":"Fine","year":"2020","journal-title":"JACC Case Rep Nov."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Eng J Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Eng J Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Eng J Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","article-title":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","volume":"37","author":"Kristen","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"B80","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.healun.2014.09.006","article-title":"Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy","volume":"34","author":"Davis","year":"2015","journal-title":"J Heart Lung Transplant May."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Europ Heart J"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging","author":"Grogan","year":"2016"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.863179\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T04:59:35Z","timestamp":1652763575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.863179\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":82,"alternative-id":["10.3389\/fcvm.2022.863179"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.863179","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"article-number":"863179"}}